newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society's 64th Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product